期刊文献+

多发性骨髓瘤治疗新进展 被引量:7

原文传递
导出
摘要 多发性骨髓瘤(multiple myeloma,MM)的传统治疗包括美法仑+泼尼松(MP)、卡氮芥+环磷酰胺+长春新碱+美法仑+泼尼松(M2)、长春新碱+阿霉素+地塞米松(VAD)、长春新碱+卡氮芥+阿霉素+强的松(VBAP)等方案。对于初治Ⅰ、Ⅱ期MM患者,MP、M2方案仍然是首选,但对于难治性、复发性MM患者疗效欠佳。VAD方案对于难治性、复发性MM患者反应率高,起效快,但生存期未见明显延长,主要用于干细胞移植前的大剂量化疗。
出处 《中国肿瘤临床与康复》 2014年第5期638-640,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 多发性骨髓瘤 治疗 进展 Multiple myeloma Treatment Progress
  • 相关文献

参考文献18

  • 1Bade J,Bosinol L,Cibeira MT,et al.Hematopoietic stem cell transplantation for multiple beyond 2010[J].Blood,2010,115:3655-3663. 被引量:1
  • 2马勇,汪兴洪.多发性骨髓瘤治疗进展[J].亚太传统医药,2012,8(4):201-203. 被引量:6
  • 3李勇华,侯健.多发性骨髓瘤治疗中值得关注的几个问题[J].肿瘤,2008,28(11):1008-1011. 被引量:5
  • 4Paul G.Barb B,et al.Extended follow up of a phase II trialIn relapsed,refractory multiple myeloma[J].Cancer,2006,106:1316-1319. 被引量:1
  • 5赵敏,屈晓燕,陈丽娟.多发性骨髓瘤治疗最新进展:第53届美国血液学会年会报道[J].白血病.淋巴瘤,2012,21(1):10-12. 被引量:5
  • 6Bruno B,Rotta M,Patriarca F,et al.A comparison of allografting with autografting for newly diagnosed myeloma[J].N Eng l J Med,2007,356:1110-1120. 被引量:1
  • 7Kukreja A,Hutchinson A,Dhodapkar K,et al.Enhancement of clonogenicity of human multiple myeloma by dendritic cells[J].J Exp Med,2006,203:185918-185965. 被引量:1
  • 8Rozkova D,Tiserova H,Fucikova J,et al.FOCUS on FOCIS:Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer[J].Clin Immunol,2009,131:1-10. 被引量:1
  • 9Pievani A.Belussi C,Klein C,et al.Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell(CIK)cultures and anti-CD20 antibodies[J].J Immunol,2011,117:510-518. 被引量:1
  • 10Di Bernardo A,Macor P,Guarnotta C,et al.Humoral immunotherapy of multiple myeloma:perspectives and perplexities[J].Expert Opin Biol The,2010,10:863-873. 被引量:1

二级参考文献39

  • 1ATFAL M, HAROUSSEAU J L, STOPPA A M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome[J]. N Engl J Med, 1996,335(2) :91-97. 被引量:1
  • 2BARLOGIE B, SHAUGHNESSY J, TRICOT G, et al. Treatment of multiple myeloma[ J]. Blood, 2004,103 ( 1 ) :20-32. 被引量:1
  • 3BARLOGIE B, KYLE R A, ANDERSON K C, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase Ⅲ US Intergroup Trial S9321 [J]. J Clin Oncol, 2006,24(6) :929-936. 被引量:1
  • 4KYLE RA, LEONG T, LI S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation [ J ]. Cancer, 2006,106(9) : 1958-1966. 被引量:1
  • 5PALUMBO A, BRINGHEN S, CARAVITA T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial [ J ]. Lancet, 2006,367 (9513) :825-831. 被引量:1
  • 6MATEOS M V, HERNANDEZ J M, HERNANDEZ M T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a muhicenter phase 1/2 study [ J ]. Blood, 2006,108 ( 7 ) :2165-2172. 被引量:1
  • 7NIESVIZKY R, RICHARDSON PG, SONNEVELD P, et al. Relationship between quality of response to Bortezomib and clinical benefit in multiple myeloma [ J ]. Blood, 2006,108 ( 11 ) : 1007 a. 被引量:1
  • 8RICHARDSON P G, SONNEVELD P, SCHUSTER M W, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005,352(24) :2487-2498. 被引量:1
  • 9WEBER DM, CHEN C, NIESVIZKY R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America [J]. N Engl J Med, 2007,357(21 ) :2133-2142. 被引量:1
  • 10OIVANEN T M, KELLOKUMPU-LEHTINEN P, KOIVISTO A M, et al. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish leukaemia group study[ J]. Eur J Haematol, 1999,62 (2) : 109-116. 被引量:1

共引文献13

同被引文献58

引证文献7

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部